Following concerns over psychiatric side effects associated with some anti-smoking drugs, researchers indicate that a new study was unable to find a link between and use of Chantix, Wellbutrin or Zyban and an increased risk of suicide.
According to findings published last week by the British Medical Journal, researchers from the University of Bristol could not identify a link between smoking cessation drugs and an increased risk of suicide.
The study comes after the makers of Chantix have settled thousands of lawsuits over claims that the drug caused users to experience psychological problems, including suicidal tendencies and violent, irrational behavior.
Researchers looked at data on 119,546 men and women who used a smoking cessation product between September 2006 and October 2011. Of those, 6,741 used bupropion, sold under the brand names Wellbutrin and Zyban, and another 31,260 used Chantix. The rest used some other smoking cessation products, such as nicotine replacement therapy (NRT).
The study found that there was no evidence that patients prescribed Chantix, Wellbutrin, or Zyban were at higher risk of fatal or non-fatal self harm or depression. The researchers determined that according to their findings there was no such risk.
Similar findings were reported last month in the Annals of Internal Medicine by researchers from the University of California and the Department of Veterans Affairs, which also failed to find a link between Chantix side effects and an increased suicide risk.
Chantix Suicide ConcernsChantix (varenicline) is a Pfizer drug designed to help smokers quit. The drug works by reducing the positive feelings that come from cigarettes, blocking the receptors in the brain commonly stimulated by nicotine. However, a few years after the drug was introduced and heralded as a potential blockbuster medication in 2006, reports began to surface of users committing suicide or engaging in sudden, unusual behavior.
In June 2009, the FDA added a
View the Original article
No comments:
Post a Comment